DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0204486A1 Pyke Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0204486A1 Pyke Et Al US 20060204486A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0204486A1 Pyke et al. (43) Pub. Date: Sep. 14, 2006 (54) PHARMACEUTICAL COMPOSITIONS FOR Publication Classification THE TREATMENT AND/OR PREVENTION OF SCHIZOPHRENA AND RELATED (51) Int. Cl. DISEASES A6II 38/54 (2006.01) A6II 3/55 (2006.01) (75) Inventors: Robert Pyke, New Fairfield, CT (US); A61K 3.1/5415 (2006.01) Angelo Ceci, Mittlebiberach (DE) A 6LX 3/59 (2006.01) A6II 3L/496 (2006.01) Correspondence Address: A6II 3/445 (2006.01) MICHAEL P. MORRIS A6II 3/405 (2006.01) BOEHRINGERINGELHEM CORPORATION A6II 3L/98 (2006.01) 900 RIDGEBURY ROAD (52) U.S. Cl. ................... 424/94.2: 514/254.06; 514/220; P. O. BOX 368 514/259.41: 514/419; 514/317; RIDGEFIELD, CT 06877-0368 (US) 514/561; 514/225.8 (73) Assignee: Boehringer Ingelheim International GmbH, Ingelheim (DE) (57) ABSTRACT (21) Appl. No.: 11/364,306 The invention relates to new pharmaceutical compositions for the treatment and/or prevention of schizophrenia and (22) Filed: Feb. 28, 2006 methods for the preparation thereof. In a preferred embodi ment, the instant invention is directed to pharmaceutical Related U.S. Application Data combinations comprising flibanserin as one active ingredi ent in combination with at least one additional active ingre (60) Provisional application No. 60/658,566, filed on Mar. dient for the treatment and/or prevention of schizophrenia 4, 2005. and methods for the preparation thereof. US 2006/0204486 A1 Sep. 14, 2006 PHARMACEUTICAL COMPOSITIONS FOR THE antagonists, alpha 2 adrenoreceptor antagonists, AMPA TREATMENT AND/OR PREVENTION OF modulators and NK 3 antagonists. SCHIZOPHRENA AND RELATED DISEASES 0007 Especially preferred are pharmaceutical composi 0001. The invention relates to new pharmaceutical com tions comprising a therapeutically effective amount of fli positions for the treatment and/or prevention of Schizophre banserin 1 in combination with a therapeutically effective nia and related diseases and methods for the preparation amount of one or more, preferably one antipsychotic drug 2 thereof. In a preferred embodiment, the instant invention is selected from the group consisting of D2 antagonists. directed to pharmaceutical combinations comprising fli banserin as one active ingredient in combination with at 0008. The compositions according to the invention may least one additional active ingredient for the treatment contain flibanserin 1 and the one or more additional antip and/or prevention of Schizophrenia and related diseases and sychotic drugs 2 in a single formulation or in separate methods for the preparation thereof. formulations. If flibanserin and the one or more additional antipsychotic drugs are present in separate formulations BACKGROUND OF THE INVENTION these separate formulations may be administered simulta neously or sequentially. 0002 The invention relates to new pharmaceutical com positions for the treatment and/or prevention of Schizophre 0009. A preferred embodiment according to the invention nia and related diseases and methods for the preparation is directed to pharmaceutical compositions comprising a thereof. In one embodiment, the instant invention is directed therapeutically effective amount of flibanserin 1 and a to pharmaceutical combinations comprising a therapeuti therapeutically effective amount of one or more, preferably cally effective amount of flibanserin 1 as one active ingre one additional antipsychotic drug. 2, optionally in combina dient of combination with a therapeutically effective amount tion with a pharmaceutically acceptable excipient. of at one or more, preferably one additional antipsychotic 00.10 Examples of suitable additional antipsychotic drug 2 for the treatment and/or prevention of Schizophrenia drugs include Chlorpromazine. Thioridazine, Haloperidol, and related diseases and methods for the preparation thereof. Perphenazine. Thiothixene, Trifluoperazine, Fluphenazine, 0003. The compound 1—2–(4 (3 trifluoromethyl Clozapine, Risperidone, Olanzapine, Quetiapine, Pimozide, phenyl)ethyl-2,3-dihydro-1H-benzimidazol-2-one (fli Aripiprazole, Ziprasidone, Perospirone, Nemonapride, banserin) is disclosed in form of its hydrochloride in Euro Sertindole, Levosulpiride, Tandospirone, Bifeprunox, pean Patent Application EP-A-526434 and has the following Asenapine, Paliperidone, Mifepristone, Lamotrigine, Ilo chemical structure: peridone, Blonanserin, DU-125530, Lurasidone, ACP-103. Idazoxan, Org-24448, CX-516, Aplindore, SLV-313, SLV 310, Ocaperidone, PNU-170413, POL-255, ABT-089 Taln O etant, NE-100, LAX-101, LAX-111, RG-1068 (Secretin), Dexefraoxan, Dihydrexidine, SM-13496, D-Serine, Osanet is-( ant, EMR-62218, SB-399885, TC-1698, SR-147778, SLV 319, SSR-181507, AVE-5997, PNU-177864, Abaperidone, SSR-146977, Neboglamine, Lamictal XT, N-Desmethyl \-O-(S\ / clozapine, Topiramate and cycloserine, optionally in form of 1 x HC the pharmaceutically acceptable acid addition salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual 0004 Flibanserin shows affinity for the 5-HT5-HT enantiomers or racemates thereof. and D-receptor. It is therefore a promising thereapeutic 0011 Flibansering 1 may be used inform of the free base, agent for the treatment of a variety of diseases, for instance optionally in form of its pharmaceutically acceptable acid depression, Schizophrenia, Parkinson, anxiety, sleep distur addition salts and/or optionally in form of the hydrates bances, sexual and mental disorders and age associated memory impairment. and/or solvates thereof. Suitable acid addition salts include for example those of the acids selected from, Succinic acid, 0005 One embodiment of the invention is directed to hydrobromic acid, acetic acid, fumaric acid, maleic acid, pharmaceutical compositions comparing a therapeutically methaneSulphonic acid, lactic acid, phosphoric acid, hydro effective amount of flibanserin 1 in combination with a chloric acid, Sulphuric acid, tartaric acid and citric acid. therapeutically effective amount of one or more additional Mixtures of the abovementioned acid addition salts may also antipsychotic drugs 2. be used. From the aforementioned acid addition salts the hydrochloride and the hydrobromide, particularly the hydro 0006 Another embodiment of the invention is directed to pharmaceutical compositions comprising a therapeutically chloride, are preferred. If flibanserin1 is used in form of the effective amount of flibanserin 1 in composition with a free base, it is preferably used in form of flibanserin poly therapeutically effective amount of one or more, preferably morph A as disclosed in WO 03/014079. one antipsychotic drug 2 selected from the group consisting 0012. The antipsychotic drugs 2 which are suitable to be of 5-HT1A agnostics, dopamine modulators, sodium channel combined with flibanserin within the teaching of the instant blockers, 5-HT uptake inhibitors, D3 antagonists, D2 invention and which are mentioned hereinbefore may also antagonists, D1 antagonists, D1 agonists, secretin agonist, be capable of forming acid addition salts with pharmaceu phospholipase A2 inhibitors, 5-HT2 antagonists, 5HT6 tically acceptable acids. Representative salts include the antagonists, COX 2 inhibitors, 5-HT2A antagonists, 5HT following: Acetate, Benzenesulfonate, Benzoate, Bicarbon modulators, NK3 antagonists, alpha 1 adrenoreceptor ate, Bisulfate, Bitartrate, Borate, Bromide, Camsylate, Car US 2006/0204486 A1 Sep. 14, 2006 bonate, Chloride, Clavulanate, Citrate, Dihydrochoride, together in one pharmaceutical composition. In addition, the Edetate, Edisylate, Estolate, Esylate, Fumarate, Gluceptate, administration of one element of the combination of the Glyconate, Glutamate, Glycolylarsanilate, Hexylresorci present invention may be prior to, concurrent to, or Subse nate, Hydrabamine, Hydrobromide, Hydrochloride, quent to the administration of the other element of the Hydroxynaphthoate, Iodide, Isothionate, Lactate, Lacto combination. bionate, Luarate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate. Mucate, 0022. The elements of the combination of 1 and 2 may be Napsylate, Nitrate, N-methylglucamine ammonium salt, administered by oral, parenteral (e.g., intramuscular, intra Oleate, Oxalate, Pamoate (Embonate), Palmitate, Pantoth peritoneal, intravenous or Subcutaneous injection or enate, Phosphate/diphosphate, Polygalacturonate, Salicy implant), buccal, nasal, vaginal, rectal, Sublingual, or topical (e..a... ocular eyedrop) routes of administration and may be late, Stearate, Sulfate, Subacetate, Succinate, Tannate, Tar formulated, alone or together, in Suitable dosage unit for trate, Teoclate, Tosylate, Triethiodide and Valerate. mulations containing conventional non-toxic pharmaceuti 0013 Furthermore, where the compounds 2 carry an cally acceptable carriers, adjuvants and vehicles appropriate acidic moiety, Suitable pharmaceutically acceptable salts for each route of administration. thereof may include alkali metal salts, e.g., Sodium or potassium salts; alkaline earth metal salts, e.g., calcium or 0023 The pharmaceutical compositions for the adminis magnesium salts; and salts formed with Suitable organic tration of the components 1 and 2 of this invention may ligands, e.g., quaternary ammonium salts. conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of 0014. The compounds 2 may have chiral centers and pharmacy.
Load more

Recommended publications
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • ZHONG-THESIS-2016.Pdf
    ANTIDEPRESSANTMINING AZ AMAZ DESIGNING A WEBBASED ALGORITHM AND VISUAL LANGUAGE FOR ANTIDEPRESSANT DRUG SELECTION TO EDUCATE PRIMARY CARE PRACTITIONERS By Amy Zhong A thesis submitted to Johns Hopkins University in conformity with the requirements for the degree of Master of Arts Baltimore, Maryland March, 2016 © 2016 Amy Zhong All Rights Reserved ABSTRACT Depression is a common mental disorder that affects approximately 14.8 million American adults each year. In addition to being a debilitating condition, depression often occurs in tandem with other medical conditions such as diabetes, heart disease, and cancer. While psychiatric professionals are essential for the management of mental health, majority of patients seek care from their primary care practitioners. This phenomenon is of great concern because diagnosis of depression within primary care settings has only been accurate 25-50% of the time. The antidepressant drug selection algorithm utilizes a unique formula to integrate patient and family medical histories, patient symptoms, and patient preferences to make optimal treatment selections. The development of a visual language explores the use of graphic elements to improve understanding of major pharmacological mechanisms, knowledge essential to making rational DQWLGHSUHVVDQWGUXJVHOHFWLRQV,QFUHDWLQJWKLVPRELOHZHEEDVHGDSSOLFDWLRQZHKRSHWR¿OOD void in resources available to primary care practitioners, and improve management of mental health within the primary care setting. By Amy Zhong Chairpersons of the Supervisory Committee Adam I. Kaplin, M.D., Ph.D., esis Preceptor Assistant Professor, Departments of Psychiatry and Neurology e Johns Hopkins University School of Medicine Kristen Rahn Hollinger, Ph.D., esis Preceptor Instructor, Departments of Psychiatry and Neurology e Johns Hopkins University School of Medicine Jennifer E.
    [Show full text]
  • Bifeprunox: a Novel Antipsychotic Agent with Partial Agonist Properties at Dopamine D2 and Serotonin 5-HT1A Receptors
    DRUG EVALUATION Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors Marie-Louise G Most second-generation, atypical, dopamine (DA) D2/5-HT2 blocking antipsychotics still Wadenberg induce extrapyramidal side effects (EPS) in higher doses. Weight gain and metabolic University of Kalmar, disturbances are also a problem, and negative and cognitive symptoms have not been Department of Natural Sciences, Norra Vagen 49, sufficiently addressed. The current brain DA mesolimbic hyperactive/mesocortical SE-391 82 Kalmar, Sweden hypoactive hypothesis of schizophrenia suggests that DA D2/5-HT1A receptor partial agonist Tel.: +46 480 446 277; properties may be more efficacious with less side effects. DA D2 receptor partial agonists Fax: +46 480 446 244; may stabilize a hyperactive/hypoactive DA condition. Additional 5-HT stimulation may marie-louise.wadenberg@ 1A hik.se enhance therapeutic efficacy and also improve EPS liability profile. In clinical trials in schizophrenic patients, the novel DA D2/5-HT1A partial agonist bifeprunox indeed demonstrates therapeutic efficacy, a safe EPS profile and appears beneficial regarding weight gain, prolactin, blood lipid and glucose levels and cardiac rhythm. The data on bifeprunox are promising and suggest that combined DA D2/5-HT1A partial agonism may well be important properties for future-generation antipsychotics. Bifeprunox, a novel antipsychotic agent with a (DA D1, D2, D4, 5-HT2A/C, 5-HT1A, hista- so-called third-generation atypical pharmacolog- mine H1, α1, α2, cholinergic muscarinic recep- ical profile, is currently in clinical trials and tor affinity) and comparatively lower affinity for expected to launch as a schizophrenia therapy in the DA D2 receptor than traditional APDs.
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • HTR1A Polymorphisms and Clinical Efficacy Of
    International Journal of Neuropsychopharmacology, (2016) 19(5): 1–10 doi:10.1093/ijnp/pyv125 Advance Access publication November 14, 2015 Research Article research article HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis Yoshiteru Takekita, MD, PhD; Chiara Fabbri, MD; Masaki Kato, MD, PhD; Yosuke Koshikawa, MA; Aran Tajika, MD; Toshihiko Kinoshita, MD, PhD; Alessandro Serretti, MD, PhD Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Drs Takekita, Fabbri, and Serretti); Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan (Drs Takekita, Kato, Koshikawa, and Kinoshita); Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan (Dr Tajika). Correspondence: Yoshiteru Takekita, MD, PhD, Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Viale Carlo Pepoli 5, Bologna, 40123, Italy ([email protected]). Abstract Background: This meta-analysis was conducted to evaluate whether HTR1A gene polymorphisms impact the efficacy of antipsychotic drugs in patients with schizophrenia. Methods: Candidate gene studies that were published in English up to August 6, 2015 were identified by a literature search of PubMed, Web of Science, and Google scholar. Data were pooled from individual clinical trials considering overall symptoms, positive symptoms and negative symptoms, and standard mean differences were calculated by applying a random-effects model. Results: The present meta-analysis included a total of 1281 patients from 10 studies. Three polymorphisms of HTR1A (rs6295, rs878567, and rs1423691) were selected for the analysis. In the pooled data from all studies, none of these HTR1A polymorphisms correlated significantly with either overall symptoms or positive symptoms.
    [Show full text]
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • Flibanserin (Addyi)
    STEPS New Drug Reviews Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder in Premenopausal Women HARRY HOLT, MD, and JEFFREY TINGEN, PharmD, MBA, University of Virginia Health System, Charlottesville, Virginia STEPS new drug reviews Flibanserin (Addyi) is labeled for the treatment of acquired, generalized hypoactive sexual cover Safety, Tolerability, desire disorder (HSDD) in premenopausal women. It is a nonhormonal medication that Effectiveness, Price, and 1 Simplicity. Each indepen- affects serotonin receptors to increase libido. dent review is provided by authors who have no financial association with Drug Dosage Dose form Cost* the drug manufacturer. Flibanserin (Addyi) 100 mg per day at bedtime 100-mg tablet $830 This series is coordinated by Allen F. Shaughnessy, *—Estimated retail price of one month’s treatment based on information obtained at http://www.goodrx.com PharmD, MMedEd, (accessed April 1, 2016). Contributing Editor. A collection of STEPS pub- lished in AFP is available at http://www.aafp.org/ SAFETY EFFECTIVENESS afp/steps. The main risks of flibanserin are hypoten- Flibanserin has been evaluated in three ran- sion (2%) and syncope (0.4%), which are domized, double-blind, placebo-controlled more likely to occur in patients who have studies of 2,375 premenopausal women also ingested alcohol. For this reason, women with acquired, generalized HSDD, defined should not drink alcohol when taking fliban- as low sexual desire causing marked dis- serin; about one in six persons taking this tress or interpersonal difficulties.2 Women combination will experience clinically signif- in monogamous, heterosexual relationships icant hypotension and syncope.1 Flibanserin with no known cause of HSDD reported should not be taken by women with hepatic an average increase of 1.6 to 2.5 additional impairment or women who are also taking satisfying sexual events per month with treat- moderate or strong cytochrome P450 3A4 ment, from a baseline of 2.5 to 3.0 per month.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]
  • Dosing and Monitoring: Children and Adolescents
    Dosing and Monitoring: Children and Adolescents Glenn S. Hirsch, MD Keith S. Ditkowski, MD Child & Adolescent Dosing.indd 1 08-01-2018 14:56:52 Adapted from Child & Adolescent Dosing.indd 76 08-01-2018 14:56:50 DISCLAIMER This pocket reference is provided as a service to medicine by the publisher, Medworks Media Inc. This review does not imply the publisher’s agreement with the views expressed herein. Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher, nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation. In an effort to allow for the widest distribution of these guidelines, the authors have modified the originally printed material to more closely conform to the limitations of product labeling. For many of the drugs discussed herein, initiation at lower doses may increase tolerability and efficacy. Copyright ©2018, MedWorks Media Inc., 2205 Rockefeller Lane, Redondo Beach, CA 90278. Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form. Child & Adolescent Dosing.indd 2 08-01-2018 14:56:52 Dosing and Monitoring: Children and Adolescents Glenn S. Hirsch, MD Keith S. Ditkowski, MD Dr. Hirsch is the deputy director of the New York University Child Study Center, the medical director in the Division of Child and Adolescent Psychiatry, and the assistant professor of psychiatry at the New York University School of Medicine.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • (Flibanserin) (Flibanserin) Tablets
    ™ MEDICATION GUIDE addyi ADDYI™ (add-ee) (flibanserin) (flibanserin) Tablets Read this Medication Guide before you start taking ADDYI™ and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor. What is the most important information I should know about ADDYI? Your risk of severe low blood pressure and fainting (loss of consciousness) is increased if you take ADDYI and: • drink alcohol. Do not drink alcohol if you take ADDYI. • take certain prescription medicines, over-the-counter medicines, or herbal supplements. Do not take or start taking any prescription medicines, over-the-counter medicines, or herbal supplements while taking ADDYI until you have talked with your doctor. Your doctor will tell you if it is safe to take other medicines or herbal supplements while you are taking ADDYI. • have liver problems. Do not take ADDYI if you have liver problems. If you take ADDYI and you feel lightheaded or dizzy, lie down right away. Get emergency medical help or ask someone to get emergency medical help for you if the symptoms do not go away or if you faint (lose consciousness). If you faint (lose consciousness), tell your doctor as soon as you can. ADDYI is only available through the ADDYI Risk Evaluation and Mitigation Strategy (REMS) Program because of the increased risk of severe low blood pressure and fainting (loss of consciousness) with alcohol use. You can only get ADDYI from pharmacies that are enrolled in the ADDYI REMS Program. For more information about the Program and a list of pharmacies that are enrolled in the ADDYI REMS Program, go to www.AddyiREMS.com or call 1-844-PINK-PILL (1-844- 746-5745).
    [Show full text]